Latest news with #Caroline
Yahoo
an hour ago
- Business
- Yahoo
Parents have just days to book free activities and meals for their children
Parents in Swindon have just days left to access free summer holiday activities and meals for their children. The Government-funded Holiday Activities and Food Programme (HAF) is closing for bookings on Monday, July 28. The initiative is designed to support eligible families by providing activities such as football and crafts, along with a hot meal, during the summer break. All eligible parents should have received a HAF programme voucher from their child's school. Be the first to know with the Swindon Advertiser! 📱 💡 Our flash sale brings the latest local happenings directly to you. Save over 50% on an annual subscription now. 🔗 #SpecialOffer — Swindon Advertiser (@swindonadver) July 4, 2025 This voucher allows you to book 16 free activities for your child throughout the summer holidays. Caroline, a mother whose daughter attended the programme last year, said: "My husband and I are very grateful for the programme. "It is hard for me to take them out with my youngest, so it is a huge blessing for our family." Read more: Manager celebrates 'incredible milestone' at town's oldest business The HAF programme has been praised by many parents for offering more than just activities and meals, but also providing a safe and fun environment for children to enjoy during the holidays. The programme is seen as a crucial support for families during the summer break, helping to ease the burden of childcare and providing enriching experiences for children. Parents are urged not to miss out on this opportunity and to book the remaining activities before the deadline.
Metro
7 hours ago
- Entertainment
- Metro
British rock icon, 63, expecting baby with wife, 38, after 'secret' wedding
An icon of British rock has revealed that he is expecting a baby with his wife after their 'secret' wedding. Tears for Fears musician Roland Orzabal, 63, shared the news that his wife Emily Rath, 38, is pregnant in a romantic post on Instagram. His wife can be seen posing in front of a beautiful rock backdrop with plants as she holds her bump. The couple, who live in the Hollywood Hills, privately tied the knot back in 2020 after the pandemic changed their wedding plans. Discussing their special day, Emily, who is a photographer, told The Sun: 'We had to postpone our original wedding date in September 2020 because of Covid. 'I felt as all corona brides have been feeling: angry, sad, gypped, and confused as to when we should have a wedding. 'Roland and I were in the States for work. We desperately wanted to get married, even just legally, and so to honour our original date, we secretly eloped, just the two of us, atop a mountain in Aspen. It was the most magical moment of my life. 'It breaks my heart that my family could not be there to see it, but no one wanted to risk their safety. 'Two weddings was never my dream, but we adapted, separating the legal wedding from the celebratory wedding to come.' She went on to say: 'In September we were able to use the autumnal flowers we'd originally wanted, and next year we can have all of the spring flowers!' We've teamed up with Camp Bestival Dorset to give one lucky Metro reader and their family the chance to win family weekend tickets, worth up to £1,172! Created by families, for families, Camp Bestival combines all the fun of a fantastic family camping holiday with everything you would expect from a perfect and action-packed festival adventure. Headliners include music legend Sir Tom Jones, pop icons Sugababes, plus a carnival-filled live show from electronic music duo Basement Jaxx. Simply enter your details here to be in with a chance of winning four tickets to this epic experience. You have until midnight on 23 July to enter. Good luck! * Open to GB residents (excluding Northern Ireland) aged 18+. Promotion opens at 18:01 on 16/7/25 and closes at 23:59 on 23/7/25. Entrant must submit their first and last name, email address, date of birth and postcode when prompted via the entry form available on (available here). 1 prize available of a family weekend camping ticket, including two (2) adult tickets and up to four (4) child and/or teen tickets in any combination as chosen by the winner to attend Camp Bestival (Lulworth Castle, Dorset) from 31st July 2025 to 3rd August 2025. Maximum 1 entry per person. Attendance is governed by the Camp Bestival Terms and Conditions. Full T&Cs apply, see here. Roland was previously married to Caroline, who died in 2017 at the age of 54 following a battle with alcoholism-related dementia and cirrhosis.. He has two sons with Caroline, called Pascal and Raoul. This difficult period in his life was said to have inspired his 2022 album The Tipping Point. Roland, who was raised in Portsmouth, is one half of the legendary band Tears for Fears alongside Curt Smith, 64. The band are known for some huge hits, such as 1984's Shout and 1985's Everybody Wants to Rule the World and Head Over Heels. Got a story? If you've got a celebrity story, video or pictures get in touch with the entertainment team by emailing us celebtips@ calling 020 3615 2145 or by visiting our Submit Stuff page – we'd love to hear from you. MORE: What really happened the night Ozzy Osbourne ripped a bat's head off with his teeth MORE: British rock band cancels tour dates after 'unexpected and catastrophic event' at member's home MORE: Rock legend worth £110,000,000 shocks fans on £47 Ryanair flight to Bristol
Sky News AU
21 hours ago
- Entertainment
- Sky News AU
'Magic': The $5 Bunnings item Australians just can't get enough of
A US based cleaning expert has detailed a new hack to clean her trainers, and it is found in the aisles of a titan of Australian retail. Caroline Solomon shares cleaning content to her social media channels, including a thread of videos that have show her trying to clean dirty trainers. A But there is one video that she has posted which has led to a popular product sold in Australia repurposed as a cleaner for dirty trainers. 'I'm sharing two easy ways to make your white leather sneakers look brand new again,' Caroline said at the start of the video that she posted to her TikTok. 'The first thing you need of course is a Magic Eraser,' she told her followers on the video sharing sight. In Australia, the item in question is sold as a Mr Clean Eraser pad for $4.98, or a four pack which sells for $7.49. Caroline explained the method to clean dirty white sneakers with the Magic Eraser, starting by first running the melamine sponge under water to get it 'damp, but not soaked'. Then, she demonstrated gently scrubbing the foam block along both 'the sneaker and the rubber sole of the shoe'. The result? Instantly refreshed looking sneakers. Commentators were quick to praise the self-styled home guru. 'This worked for me,' read one reply. Another read 'I cut mine in half to get more use out of them that way! They get worn faster when wet so I also only wet half of sponge.' On the Bunnings website, the Mr Clean Eraser Pod Block has a 4.9 stars rating, with many reviews raving about how it 'works great' to remove scuffs and marks from walls and floors. However, none of the reviews made mention of its bonus use to clean up dirty sneakers.
Hamilton Spectator
a day ago
- Business
- Hamilton Spectator
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit . IPSEN CONTACTS Investors Khalid Deojee +33 6 66 01 95 26 Media Sally Bain +1 857 32 00 517 Anne Liontas +33 6 69 09 12 96 Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment
Business Upturn
a day ago
- Business
- Business Upturn
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product Officer is appointed to Andreas Gerber is appointed to EVP, Head of International is appointed to Caroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit . IPSEN CONTACTS Investors Khalid Deojee [email protected] +33 6 66 01 95 26 Media Sally Bain [email protected] +1 857 32 00 517 Anne Liontas [email protected] +33 6 69 09 12 96 Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Ipsen PR_ELT Changes_23072025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
